Prediction of area under the concentration-time curve for lopinavir from peak or trough lopinavir concentrations in patients receiving lopinavir-ritonavir therapy

被引:1
作者
Srinivas, Nuggehally R. [1 ]
机构
[1] Suramus Bio, Bangalore, Karnataka, India
关键词
REVERSE-TRANSCRIPTASE INHIBITORS; HIV-INFECTED PATIENTS; STEADY-STATE PHARMACOKINETICS; DRUG-DRUG INTERACTIONS; 48 WEEK EFFICACY; ANTIRETROVIRAL THERAPY; HIV-1-INFECTED PATIENTS; PLASMA-CONCENTRATIONS; 3RD TRIMESTER; LOPINAVIR/RITONAVIR;
D O I
10.2146/ajhp150417
中图分类号
R9 [药学];
学科分类号
1007 ;
摘要
Purpose. A "single time point" strategy for predicting the area under the concentration-time curve (AUC) for lopinavir in patients receiving ritonavir-boosted lopinavir therapy was investigated. Methods. Linear regression equations describing the relationships of lopinavir peak and trough concentrations to lopinavir AUC values were established using pharmacokinetic data from published studies of patients or healthy subjects receiving lopinavir and ritonavir at standard dosages. The resulting "trough-AUC model" and "peak-AUC model" were used to predict lopinavir AUC values in the evaluated study populations (total n = 479); those values were then compared with reported AUC values. Results. Lopinavir peak or trough concentrations were strongly correlated with lopinavir AUC values (r = 0.9947 and r = 0.9541, respectively). For about 94% of calculations using the peak-AUC model and 87% of calculations using the trough-AUC model, differences between predicted and observed AUC values were in the range of 0.76-1.5 fold; the associated r values were 0.9514 (p < 0.001) and 0.9345 (p < 0.001), respectively. The mean absolute predictive error was less than 6% with the use of either the peak-AUC model or the trough-AUC model, with corresponding values for root-mean-square error of 17.6% and 23.5%, respectively. Conclusion. Equations incorporating lopinavir peak and trough concentrations were found to satisfactorily predict lopinavir AUC values in data sets describing patients receiving lopinavir with ritonavir boosting. Variability in predictions was higher with use of the trough-AUC model.
引用
收藏
页码:376 / 385
页数:10
相关论文
共 57 条
[1]  
[Anonymous], GUIDELINES USE ANTIR
[2]   The Observed Correlation between in vivo Clinical Pharmacokinetic Parameters and in vitro Potency of VEGFR-2 Inhibitors [J].
Benjamin, B. ;
Sahu, M. ;
Bhatnagar, U. ;
Abhyankar, D. ;
Srinivas, N. R. .
ARZNEIMITTELFORSCHUNG-DRUG RESEARCH, 2012, 62 (04) :194-201
[3]   Pharmacokinetics of Lopinavir/Ritonavir Crushed Versus Whole Tablets in Children [J].
Best, Brookie M. ;
Capparelli, Edmund V. ;
Diep, Huy ;
Rossi, Steven S. ;
Farrell, Michael J. ;
Williams, Elaine ;
Lee, Grace ;
van den Anker, John N. ;
Rakhmanina, Natella .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2011, 58 (04) :385-391
[4]   Lopinavir Tablet Pharmacokinetics With an Increased Dose During Pregnancy [J].
Best, Brookie M. ;
Stek, Alice M. ;
Mirochnick, Mark ;
Hu, Chengcheng ;
Li, Hong ;
Burchett, Sandra K. ;
Rossi, Steven S. ;
Smith, Elizabeth ;
Read, Jennifer S. ;
Capparelli, Edmund V. .
JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES, 2010, 54 (04) :381-388
[5]  
Boehringer Ingelheim Pharmaceuticals Inc, VIR NEV PRESCR INF
[6]   Utility of therapeutic drug monitoring in the management of HIV-infected pregnant women in receipt of lopinavir [J].
Caswell, R. J. ;
Phillips, D. ;
Chaponda, M. ;
Khoo, S. H. ;
Taylor, G. P. ;
Ghanem, M. ;
Poulton, M. ;
Welch, J. ;
Gibbons, S. ;
Jackson, V. ;
Lambert, J. S. .
INTERNATIONAL JOURNAL OF STD & AIDS, 2011, 22 (01) :11-14
[7]   Early Initiation of Lopinavir/Ritonavir in Infants Less Than 6 Weeks of Age Pharmacokinetics and 24-Week Safety and Efficacy [J].
Chadwick, Ellen Gould ;
Pinto, Jorge ;
Yogev, Ram ;
Alvero, Carmelita G. ;
Hughes, Michael D. ;
Palumbo, Paul ;
Robbins, Brian ;
Hazra, Rohan ;
Browning, Leslie ;
Heckman, Barbara E. ;
Purdue, Lynette ;
Browning, Renee ;
Luzuriaga, Katherine ;
Rodman, John ;
Capparelli, Edmund .
PEDIATRIC INFECTIOUS DISEASE JOURNAL, 2009, 28 (03) :215-219
[8]   Physiologically Based Pharmacokinetic Modeling to Predict Drug-Drug Interactions Involving Inhibitory Metabolite: A Case Study of Amiodarone [J].
Chen, Yuan ;
Mao, Jialin ;
Hop, Cornelis E. C. A. .
DRUG METABOLISM AND DISPOSITION, 2015, 43 (02) :182-189
[9]   Long-term response to combination antiretroviral therapy in HIV-infected children in the Netherlands registered from 1996 to 2012 [J].
Cohen, Sophie ;
Smit, Colette ;
van Rossum, Annemarie M. C. ;
Fraaij, Pieter L. A. ;
Wolfs, Tom F. W. ;
Geelen, Sibyl P. M. ;
Schoelvinck, Elisabeth H. ;
Warris, Adilia ;
Scherpbier, Henriette J. ;
Pajkrt, Dasja .
AIDS, 2013, 27 (16) :2567-2575
[10]   Dose separation does not overcome the pharmacokinetic interaction between fosamprenavir and lopinavir/ritonavir [J].
Corbett, Amanda H. ;
Patterson, Kristine B. ;
Tien, Hsiao-Chuan ;
Kalvass, Leslie A. ;
Eron, Joseph J. ;
Ngo, Linh T. ;
Lim, Michael L. ;
Kashuba, Angela D. M. .
ANTIMICROBIAL AGENTS AND CHEMOTHERAPY, 2006, 50 (08) :2756-2761